Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles matching "biotech"

Clinical trialRSSMay 14

Biotech raises $42 million to run Huntington’s disease trial

A biotech company called Latus Bio has raised $42 million in funding to support a clinical trial for Huntington's disease. This money will help them test a new treatment approach in patients with this genetic brain disorder. The funding shows that researchers are actively working on new ways to help people with Huntington's disease.

WHY IT MATTERSThis funding enables Latus Bio to move forward with testing their Huntington's disease treatment in patients, which could lead to new therapeutic options for people currently living with limited treatment choices.
👁 Watch this spaceHuntington's disease
PipelineRSSMay 7

Companies join forces to speed production of 1-time treatment for FSHD

Two companies, Epicrispr Biotechnologies and Forge Biologics, are working together to make EPI-321, a new one-time treatment for facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare muscle disease that causes progressive weakness. The treatment works by using epigenetics—a way to turn off genes without changing their DNA—to stop the abnormal gene that causes FSHD.

WHY IT MATTERSThis partnership could accelerate production of EPI-321, potentially bringing a one-time treatment option closer to FSHD patients who currently have limited approved therapies.
👁 Watch this spaceFacioscapulohumeral muscular dystrophy (FSHD)

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases